ADC reports Phase I data for ADCT-301 in Hodgkin's lymphoma

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 35 evaluable patients with Hodgkin's lymphoma in a Phase I trial showing that IV ADCT-301 (camidanlumab tesirine, Cami-T, HuMax-TAC-ADC) led to an overall response rate (ORR) of 71%. Median duration of response was 5.1 months. Data were presented at the American Society of Hematology meeting in Atlanta.

The trial is enrolling about 140 patients with relapsed or refractory B cell Hodgkin’s or non-Hodgkin’s lymphoma. The open label, U.S. and U.K. trial's primary endpoint is dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD). Secondary endpoints include ORR, duration of response, progression-free survival (PFS), overall survival (OS) and pharmacokinetics...